Compare Neurocrine Biosciences Inc (NBIX) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Realty Income Corp — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Realty Income Corp trades at $54.2 (market cap $50.48B). The key difference: Realty Income Corp is far larger — about 3.5× Neurocrine Biosciences Inc's market cap, and Realty Income Corp pays a 6.11% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Realty Income Corp for 127 Days on average.
| NBIX | O | |
|---|---|---|
Market Cap | $14.60B | $50.48B |
Volume | 1,075,694 | 6,493,749 |
Sector | Health | Real Estate |
52-Week High | $185.50 | $67.56 |
52-Week Low | $123.10 | $53.35 |
Typical Hold Time | 23 Days | 127 Days |
Enterprise Value | $14.61B | $81.11B |
Dividend Yield | — | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Realty Income (O) trades at $54.17, down 0.15% with a bearish technical signal. The stock faces pressure from rising Treasury yields but maintains strong fundamentals including 92.56% gross margins and consistent dividend payments. Recent earnings have missed expectations, though revenue growth continues with 2025 reaching $5.75B. Analyst consensus remains positive with a $64.80 price target despite technical weakness.
The stock offers income potential with its 6%+ dividend yield and 136 consecutive dividend increases, but faces headwinds from interest rate sensitivity and recent earnings misses. Long-term fundamentals remain solid with A-rated credit and near-99% occupancy, though near-term technical pressure suggests cautious entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
